摘要
Background: The comparative effectiveness of angiotensin-converting enzyme inhibitors (ACEis) versus angiotensin receptor blockers (ARBs) in heart failure with nonreduced ejection fraction (HFnon-rEF) remains uncertain. We evaluated long-term outcomes of these therapies in a real-world cohort following hospitalization for acute heart failure. Methods: This retrospective multicenter study (2005-2019) included 5837 patients with HFnon-rEF (left ventricular ejection fraction ≥ 40%). Patients were categorized by discharge prescription into ACEi, ARB, or non-renin-angiotensin system inhibitor (RASi) groups. A 14-day landmark approach ensured pharmacological stabilization and reduced time-related bias. Inverse probability of treatment weighting was used to balance covariates (SMD < 0.1). The primary outcome was a composite of cardiovascular (CV) death or heart failure rehospitalization at 1 year. Results: The primary composite outcome was similar between ARB and ACEi users (adjusted hazard ratio [HR], 0.94; 95% confidence interval [CI], 0.75-1.17; P = .556). However, ARB therapy was associated with lower all-cause mortality compared with ACEi (adjusted HR, 0.74; 95% CI, 0.55-0.99; P = .041) and non-RASi (adjusted HR, 0.80; 95% CI, 0.67-0.94; P = .008). Subgroup analyses showed generally consistent directional associations between ARB use and lower mortality, although these findings were exploratory. Conclusions: In this real-world cohort of patients with HFnon-rEF, ARB use was associated with lower all-cause mortality compared with ACEi, despite similar CV outcomes. These findings do not establish superiority and should be interpreted as hypothesis-generating.
| 原文 | 英語 |
|---|---|
| 文章編號 | 10742484261452742 |
| 頁(從 - 到) | 10742484261452742 |
| 期刊 | Journal of Cardiovascular Pharmacology and Therapeutics |
| 卷 | 31 |
| DOIs | |
| 出版品狀態 | 已出版 - 01 01 2026 |
文獻附註
Publisher Copyright:© The Author(s) 2026. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
UN SDG
此研究成果有助於以下永續發展目標
-
SDG3 健康與福祉
指紋
深入研究「Comparative Effectiveness of Renin-Angiotensin System Inhibitors in Heart Failure With Nonreduced Ejection Fraction: A Multicenter Cohort Study」主題。共同形成了獨特的指紋。引用此
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver